person · Reporting owner

JOHNSON DAVID LEE

Disclosed activity across 3 companies

Tapewire entity: 64675
SEC CIK: 0001733883

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Caribou Biosciences, Inc.CRBU · Entity 6445	Director	February 20, 2026	February 20, 2026
Vera Therapeutics, Inc.VERA · Entity 4358	Chief Operating Officer	February 23, 2026	February 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Caribou Biosciences, Inc.

Report date February 20, 2026 · Filed February 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19	Direct	45,000	Reported balance After 2026-02-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 45,000 F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Vera Therapeutics, Inc.

Report date February 23, 2026 · Filed February 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	45,727	Reported balance After 2026-02-23 transaction · row 1 1 source row Row 1 · 2026-02-23 · Sale · Disposed 2,579 · Balance 45,727 F1: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. F2: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. F3: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026.

F2: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.

F3: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2022-10-05 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-09-28 · Gift · Disposed 22,000 · Balance 34,384 Row 2 · 2022-10-05 · Disposition to issuer · Disposed 34,384 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 3,125 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 10,935 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 13,814 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 15,460 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-05 · Disposition to issuer · Disposed 26,454 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-05 · Disposition to issuer · Disposed 42,400 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.05	Direct	Reported balance After 2022-10-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-05 · Disposition to issuer · Disposed 55,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.44	Direct	Reported balance After 2022-10-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-10-05 · Disposition to issuer · Disposed 40,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.82	Direct	Reported balance After 2022-10-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-10-05 · Disposition to issuer · Disposed 38,500 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.48	Direct	Reported balance After 2022-10-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-10-05 · Disposition to issuer · Disposed 38,739 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.87	Direct	Reported balance After 2022-10-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-10-05 · Disposition to issuer · Disposed 28,628 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 23, 2026 Filed Feb 25, 2026 19:57 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	SaleClass A Common Stock	2,579	$41.98	$108,276.48	Disclosure SEC source: 0001733883-26-000006 · form4-02262026_120221.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,727 F1 · date: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. F2 · kind: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 20, 2026 Filed Feb 20, 2026 22:27 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	GrantOption to purchase Common Stock · Derivative	45,000	$0.00 Strike: $1.80	$0.00	Disclosure SEC source: 0001733883-26-000004 · wk-form4_1771626459.xml · derivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-02-19 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document
February 04, 2026 Filed Feb 6, 2026 20:00 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $42.74	$0.00	Disclosure SEC source: 0001733883-26-000002 · form4-02062026_080203.xml · derivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Class A Common Stock · 40,000 shares Expires 2036-02-03 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document
February 04, 2026 Filed Feb 6, 2026 20:00 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantClass A Common Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001733883-26-000002 · form4-02062026_080203.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,306 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. F2 · balance_after: Includes 643 shares of Class A Common Stock acquired on March 13, 2025 and 763 shares of Class A Common Stock acquired on September 12, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:14 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	GrantOption to purchase Common Stock · Derivative	40,500	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001733883-25-000003 · wk-form4_1740186872.xml · derivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2035-02-19 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document
February 18, 2025 Filed Feb 20, 2025 16:05 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantStock Option (right to buy) · Derivative	53,800	$0.00 Strike: $29.18	$0.00	Disclosure SEC source: 0001415889-25-004844 · form4-02202025_090230.xml · derivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,800 Underlying: Class A Common Stock · 53,800 shares Expires 2035-02-17 F2 · derivative.exercise_date: 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document
February 18, 2025 Filed Feb 20, 2025 16:05 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantClass A Common Stock	26,900	$0.00	$0.00	Disclosure SEC source: 0001415889-25-004844 · form4-02202025_090230.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,900 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date. Read SEC document
July 01, 2024 Filed Jul 3, 2024 16:05 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantStock Option (right to buy) · Derivative	160,000	$0.00 Strike: $36.29	$0.00	Disclosure SEC source: 0001415889-24-019162 · form4-07032024_080715.xml · derivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Class A Common Stock · 160,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on July 1, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date. Read SEC document
February 20, 2024 Filed Feb 22, 2024 22:01 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	GrantOption to purchase Common Stock · Derivative	39,500	$0.00 Strike: $6.81	$0.00	Disclosure SEC source: 0001628280-24-006407 · wk-form4_1708639272.xml · derivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,500 Underlying: Common Stock · 39,500 shares Expires 2034-02-19 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2025, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document
February 21, 2023 Filed Feb 23, 2023 21:46 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	GrantOption to purchase Common Stock · Derivative	21,500	$0.00 Strike: $6.12	$0.00	Disclosure SEC source: 0001619856-23-000016 · wf-form4_167718878109697.xml · derivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-02-20 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 21, 2024, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	28,628	Not disclosed Strike: $29.87	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 13 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,628 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	38,739	Not disclosed Strike: $44.48	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 12 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,739 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	38,500	Not disclosed Strike: $65.82	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 11 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,500 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	Not disclosed Strike: $48.44	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 10 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	55,000	Not disclosed Strike: $54.05	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 9 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	42,400	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 8 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,400 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6 · price: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. F6 · derivative.exercise_date: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. F6 · derivative.expiration_date: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	26,454	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 7 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,454 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	15,460	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 6 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,460 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	13,814	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 5 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,814 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	10,935	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 4 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,935 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	3,125	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · derivative · entry 3 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires not disclosed F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	34,384	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · nonDerivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
September 28, 2022 Filed Oct 6, 2022 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GiftCommon Stock	22,000	$0.00	$0.00	Disclosure SEC source: 0000899243-22-033150 · doc4.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,384 Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	2,208	$0.00	$0.00	Disclosure SEC source: 0000899243-22-030479 · doc4.xml · derivative · entry 6 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,460 Underlying: Common Stock · 2,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	2,763	$0.00	$0.00	Disclosure SEC source: 0000899243-22-030479 · doc4.xml · derivative · entry 5 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,814 Underlying: Common Stock · 2,763 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	2,103	$68.15	$143,319.45	Disclosure SEC source: 0000899243-22-030479 · doc4.xml · nonDerivative · entry 4 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,384 F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,971 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	2,208	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-030479 · doc4.xml · nonDerivative · entry 3 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	2,763	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-030479 · doc4.xml · nonDerivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 31, 2022 Filed Sep 6, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantCommon Stock	365	$25.37	$9,260.05	Disclosure SEC source: 0000899243-22-030479 · doc4.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,516 F1 · shares: Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
August 01, 2022 Filed Aug 3, 2022 18:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,645	$0.00	$0.00	Disclosure SEC source: 0000899243-22-027635 · doc4.xml · derivative · entry 4 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,935 Underlying: Common Stock · 3,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
August 01, 2022 Filed Aug 3, 2022 18:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,125	$0.00	$0.00	Disclosure SEC source: 0000899243-22-027635 · doc4.xml · derivative · entry 3 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
August 01, 2022 Filed Aug 3, 2022 18:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	2,342	$32.40	$75,880.80	Disclosure SEC source: 0000899243-22-027635 · doc4.xml · nonDerivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,151 F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
August 01, 2022 Filed Aug 3, 2022 18:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	6,770	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-027635 · doc4.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 299 shares of Common Stock acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
May 18, 2022 Filed May 19, 2022 00:38 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	GrantOption to purchase Common Stock · Derivative	44,000	$0.00 Strike: $9.12	$0.00	Disclosure SEC source: 0001209191-22-030288 · doc4.xml · derivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: This option becomes exercisable in three equal annual installments beginning May 18, 2023. Read SEC document
April 01, 2022 Filed Apr 5, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	4,375	$0.00	$0.00	Disclosure SEC source: 0000899243-22-013880 · doc4.xml · derivative · entry 3 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019, and with respect to 1/6th of the remaining underlying shares on a semi-annual basis thereafter through April 1, 2022. F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019, and with respect to 1/6th of the remaining underlying shares on a semi-annual basis thereafter through April 1, 2022. Read SEC document
April 01, 2022 Filed Apr 5, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	1,513	$35.91	$54,331.83	Disclosure SEC source: 0000899243-22-013880 · doc4.xml · nonDerivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,424 F2 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
April 01, 2022 Filed Apr 5, 2022 19:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	4,375	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-013880 · doc4.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to buy) · Derivative	28,628	$0.00 Strike: $29.87	$0.00	Disclosure SEC source: 0000899243-22-009262 · doc4.xml · derivative · entry 7 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,628 Underlying: Common Stock · 28,628 shares Expires 2032-02-28 F7 · derivative.exercise_date: The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	17,668	$0.00	$0.00	Disclosure SEC source: 0000899243-22-009262 · doc4.xml · derivative · entry 6 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,668 Underlying: Common Stock · 17,668 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F6 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	17,668	$0.00	$0.00	Disclosure SEC source: 0000899243-22-009262 · doc4.xml · derivative · entry 5 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,668 Underlying: Common Stock · 17,668 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	2,763	$0.00	$0.00	Disclosure SEC source: 0000899243-22-009262 · doc4.xml · derivative · entry 4 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,577 Underlying: Common Stock · 2,763 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	956	$29.87	$28,555.72	Disclosure SEC source: 0000899243-22-009262 · doc4.xml · nonDerivative · entry 3 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,562 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,763 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	2,763	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-009262 · doc4.xml · nonDerivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 28, 2022 Filed Mar 3, 2022 21:12 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantCommon Stock	472	$25.37	$11,974.64	Disclosure SEC source: 0000899243-22-009262 · doc4.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,755 F1 · shares: Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
February 01, 2022 Filed Feb 3, 2022 17:44 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,645	$0.00	$0.00	Disclosure SEC source: 0000899243-22-004634 · doc4.xml · derivative · entry 4 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,580 Underlying: Common Stock · 3,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2022 Filed Feb 3, 2022 17:44 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,125	$0.00	$0.00	Disclosure SEC source: 0000899243-22-004634 · doc4.xml · derivative · entry 3 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2022 Filed Feb 3, 2022 17:44 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	2,559	$29.33	$75,055.47	Disclosure SEC source: 0000899243-22-004634 · doc4.xml · nonDerivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,283 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,770 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
February 01, 2022 Filed Feb 3, 2022 17:44 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	6,770	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-004634 · doc4.xml · nonDerivative · entry 1 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
October 01, 2021 Filed Oct 5, 2021 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	4,375	$0.00	$0.00	Disclosure SEC source: 0000899243-21-039183 · doc4.xml · derivative · entry 3 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,375 Underlying: Common Stock · 4,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
October 01, 2021 Filed Oct 5, 2021 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	2,170	$26.25	$56,962.50	Disclosure SEC source: 0000899243-21-039183 · doc4.xml · nonDerivative · entry 2 JOHNSON DAVID LEE · CIK 0001733883 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,072 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.